Speak To Advisor
1-800-786-7235
A healthy investment in healthier futures.

Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2015 Financial Results

OLDSMAR, Fla., April 15, 2015 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2015.

Financial Results

Revenue
Consolidated revenues for the first quarter of fiscal 2015 were approximately $4.8 million compared to approximately $5.3 million for the first quarter of fiscal 2014, a 9% decrease. The revenues for the first quarter of fiscal 2015 consisted of approximately $4.7 million in processing and storage fees and approximately $169,000 in licensee income compared to approximately $4.4 million in processing and storage fees and approximately $963,000 in licensee income for the first quarter of fiscal 2014. Licensee income for the three month months ended February 28, 2014 consists of $794,000 related to royalty income from Cryo-Cell de Mexico ("Mexico") resulting from Mexico paying the remaining balance due under the amendment to the license agreement during the first quarter 2014. The remaining licensee income consists of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements.
more
Cryo-Cell Reports Financial Results for Fiscal 2014

OLDSMAR, Fla., March 3, 2015 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year 2014.

"In spite of a very competitive environment in the cord blood banking industry, Cryo-Cell International was able to increase revenues in fiscal 2014 by 6% from fiscal 2013," said David Portnoy, Cryo-Cell's Chairman and Co-CEO. "We hope to improve upon this during fiscal 2015."

Financial Results

Revenue
Consolidated revenues for fiscal 2014 were approximately $20.1 million compared to approximately $19.0 million for fiscal 2013. The revenues for fiscal 2014 consisted of approximately $18.7 million in processing and storage fee revenue and approximately $1.5 million in licensee income, compared to approximately $17.7 million in processing and storage fee revenue and approximately $1.3 million in licensee income for fiscal 2013. Licensee income for the fiscal year ended November 30, 2014 consists of $794,000 related to Cryo-Cell de Mexico ("Mexico") which is a result of Mexico paying off the remaining balance due under the amendment during the first quarter of fiscal 2014, which will not recur in future periods. The remaining licensee income consists of $677,000 in royalty income earned on the processing and storage of cord blood stem cell specimens in India per the license agreement. Licensee income for the fiscal year ended November 30, 2013 consisted of $1.3 million in royalty income earned on the processing and storage of cord blood stem cell specimens in Mexico and India where the Company has license agreements.
more
Cryo-Cell Reports Fiscal Third Quarter 2014 Results

OLDSMAR, Fla., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (the "Company") (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2014.

Financial Results

Revenue
Consolidated revenues for the third quarter of fiscal 2014 were approximately $4.9 million compared to approximately $4.8 million for the third quarter of fiscal 2013. The revenues for the third quarter of fiscal 2014 consisted of approximately $4.8 million in processing and storage fee revenue and approximately $169,000 in licensee income, compared to approximately $4.5 million in processing and storage fee revenue and approximately $324,000 in licensee income for the third quarter of fiscal 2013. The 48% decrease in licensee income for the three months ended August 31, 2014 compared to the three months ended August 31, 2013 is the result of decreased licensee income from Cryo-Cell de Mexico ("Mexico") as Mexico paid the remaining balance due under the amendment to the license agreement during the first fiscal quarter of 2014. There will be no further licensee income recognized pursuant to that agreement. The remaining licensee income (and all of the licensee income for the three months ended August 31, 2013) consists of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements.
more